With the debate swirling around the efficacy and safety of UV-C technology, an individual needs which generation the product is. Infection Control Today® continues its ongoing special reporting on UV-C technology.
Even though the germicidal effects of ultraviolet light were first discovered in 1877, currently in the health care industry, a debate of the efficacy of ultraviolet-C light (UV-C) technology continues. Also, with some investigators publishing studies showing it is safe and others not, the question comes down to which company’s technology works and what does not. Are the studies the companies are using their own, done by an independent research firm, or are the companies using competitors’ data? What generation of UV-C technology are the investigators using?
In the second of 2 segments of this exclusive Infection Control Today® (ICT®) interview with Gunner Lyslo, founder and CEO of Surfacide, continues the discussion on where the industry is going and what questions for health care facilities, schools, businesses, and others should ask when they are looking for UVC technology to keep their employees and visitors safe.
Although, UV-C has been proven to be effectual against SARS-CoV-2, some individuals still are hesitant to consider UV-C technology. Lyslo pushes back and says that second generation technology (like Surfacide) demonstrates that the technology is effective.
“It's an incredibly important technology [and] disinfection modality. And if used in an evidence-based way, with the proper indications for use, it will have a tremendous impact to the benefit of all those end users and all those individuals who are entering those spaces. [This is true] whether it would be a hospital, which hospitals are still first and foremost to [Surfacide], because that's where you're dealing with an immunocompromised patient population, as well as you're dealing with an environmental services team are frontline health care workers who have numerous workplace stresses.”
The first part of the interview with Lyslo is here.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.
The Sterile Processing Conference Survival Guide: How to Make the Most of Your Next Event
March 25th 2025From expert speakers to cutting-edge tools, sterile processing conferences, like the 2025 HSPA Annual Conference and the SoCal SPA's Spring Conference, offer unmatched opportunities to grow your skills, expand your network, and strengthen your department's infection prevention game.
Redefining Material Compatibility in Sterilization: Insights From AAMI TIR17:2024
March 24th 2025AAMI TIR17:2024 provides updated, evidence-based guidance on material compatibility with sterilization modalities. It offers essential insights for medical device design and ensures safety without compromising functionality.